Survey
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
1 UPDATE ON TANZANIA’S PILOT ACT SUBSIDY PROJECT Roll Back Malaria 13th Board Meeting 29 November 2007 Addis Ababa 2 Today’s presentation Background and context Results to date Implications and areas for further exploration Next steps and timeline 3 Malaria is one of Tanzania’s greatest health problems, taking a heavy toll on its people and burdening its health system • 85% of population at risk of stable, endemic malaria • 14 – 18 million malaria cases every year • More than 100,000 people killed, most young children • Estimated 3.4% reduction in annual GDP due to absenteeism and death • Estimated 40% of all hospital admissions due to malaria 4 Over 50% of Tanzanians seek treatment in the private sector, but there are many barriers to effective, affordable treatment Treatment-seeking behavior • Over 40% of Tanzanians seek anti-malarial treatment through the private sector: drug stores, general stores and private health facilities – Tanzania is scaling up the Accredited Drug Dispensing Outlet (ADDO) program from 4 regions to nationwide, but this is expected to take until 2010 and in the meantime many patients will continue to seek treatment at drug stores (duka la dawa baridi) Source: Hetzel et al. BMC Public Health Barriers to treatment access in the private sector • High cost of ACTs • Continuing preference for previously-used, ineffective antimalarials (e.g., Chloroquine, SP) • Dearth of drugstores in most rural, remote areas • Continuing classification of ACTs as a prescription-only medicine • Limited training of drug store dispensers • Poor packaging of drugs 5 The pilot ACT subsidy project aims to both provide data for policymaking as well as to increase access in the target areas Objectives: 1. Inform policymaking at both the national and global levels, particularly related to the introduction of an ACT subsidy, by providing evidence on the impacts of a top-level subsidy of medicines through the private sector 2. Substantially increase access to affordable, effective, high-quality malaria treatment in the targeted intervention areas Key questions: 1. What is the final price paid by patients for subsidized drugs? 2. What is the effect of a package of accompanying interventions (e.g., SRP, repackaging, social marketing) on end-user price and uptake? 3. What is the impact of the subsidy on the purchase and use of ACTs compared to other anti-malarials? Principles: 1. 2. 3. 4. 5. Maximize benefits to patients Ensure rapid initiation and implementation Work at the behest of and in close collaboration with the government and other partners Replicate normal supply chain processes and behavior Minimize leakage 6 The pilot project is being led by the Ministry of Health and Social Welfare and implemented by PSI – Tanzania and the Clinton Foundation • Lead partners: TFDA and NMCP • Manage relations with local government • Conduct dispenser training Tanzania Pilot ACT Subsidy Project • Implement in-country social marketing and repackaging • Build on lessons learned from ACT repackaging/subsidy experiences in other countries • Manage procurement of drugs and implementation of supporting interventions • Lead communication to global partners 7 Three rural districts were selected as representative of socioeconomic and malaria conditions in Tanzania and sub-Saharan Africa Shinyanga Rural: control Maswa: subsidy control District selection criteria: • High burden of stable, endemic malaria • Malaria-related DHS indicators in line with national averages • Significant number of local drug shops (duka la dawa baridi) • Socioeconomic indicators indicative of rural, poor population • Low opportunity for leakage across borders or to large cities Kongwa: price intervention • Absence of Accredited Drug Dispensing Outlets (ADDOs) 8 The project has three key components running simultaneously Monitoring & evaluation Key activities • Baseline survey of duka la dawa baridi and public/NGO health facilities • Ongoing monitoring of metrics including enduser price and anti-malarial volumes sold Procurement and distribution • Quantification of quarterly uptake of ACTs through duka la dawa baridi in target districts • Procurement of ACTs and resale to national wholesaler at a subsidized price Supporting interventions • Social marketing/behavior change communication activities focused solely in target districts • Placement of suggested retail price • Repackaging of drugs into Tanzania-specific, user-friendly Kiswahili package • Training of drugstore dispensers on proper administration of Coartem and improving malaria knowledge 1 2 Pilot ACT subsidy project 3 9 Drugs are distributed through two existing channels to the districts – via a regional distributor or direct to retailer ACT Manufacturer Clinton Foundation ACTs procured at public sector price ACTs sold to wholesaler at 90% subsidy Wholesaler Maswa District Regional Stock Point “Direct” Kongwa District Regional Distributor “Indirect” Trucks/bikes deliver direct to shops Regional Distributor “Indirect” Regional Stock Point “Direct” Shops pick up drugs from distributors Drug Shops Trucks/bikes deliver direct to shops Drug Shops 10 The packaging was designed specifically for Tanzania to encourage effective and responsible ACT distribution • Cover photos and color schemes differentiate doses • Compelling, high-quality presentation attracts demand • National brand is prominent; manufacturer brand included • Simple, clear instructions in Kiswahili and pictorially • Timing of doses clearly indicated, and reflects other specific elements of National Malaria Treatment Guidelines • Prepackaged drug from manufacturer slides into package; ensures quality and removes risk of contamination during repackaging •Expiration date on original packaging visible 11 Today’s presentation Background and context Results to date Implications and areas for further exploration Next steps and timeline 12 Four different data collection methods are being employed to ensure robust data capture Metric Exit interview • Types/brands of anti-malarials sold/stocked (incl. subsidized product) • Volume of subsidized ACT and other antimalarial sales • Sale price per dose • Package conditions – loose, original, etc. • Availability and stocks of Coartem in nearby public/NGO sector health facilities • Intended recipient of drugs • Age and gender of patient • Socioeconomic status of purchaser’s household • Reason for purchase • Location (peri-urban vs. rural) and clustering/competition Mystery shopper Retail Public/NGO audit sector audit GPS 13 The subsidized ACTs have quickly gained market share, appearing to displace AQ for adults… Breakdown of products purchased in August vs. November % of adult exit interviews 100% = Other Quinine 458 343 5% 17% 4% Subsidized ACT 1% 26% 4% 15% Amodiaquine 64% 64% SP Nonsubsidized 1% ACT + monotherapy 2% August November 14 … and children Breakdown of products purchased in August vs. November % of exit interviews purchasing for a child under 5 100% = 79 87 Other 1% Quinine 1% 26% Subsidized ACT 6% 90% Amodiaquine SP 57% 8% August 11% November 15 Price paid for subsidized ACTs is in line with other commonlyavailable anti-malarials, and the SRP appears to be effective Mean and standard deviation of price paid % of adult exit interviews buying a full dose Tanzanian Shillings 3,500 3,000 2,500 2,000 1,500 1,000 500 0 Subsidized ACT SP In the price intervention district, the maximum price paid did not exceed the SRP of TSH 1200 AQ Art. Monotherapy 16 The majority of patients are getting a full course of anti-malarials Share of patients purchasing a full dose % of 440 exit interviews Subsidized ACT Any SP Any AQ 81% 61% 84% 17 The importance of shopkeeper recommendation is reinforced, particularly for subsidized ACTs Reasons for buying each drug % of 443 exit interviews Shopkeeper recommendation Subsidized ACT Any SP Any AQ Prescribed 51 22 28 13 42 40 12 Previous use Most effective 1 12 16 25 Price 8 4 7 9 18 There continues to be no consumers from the poorest socioeconomic quintile purchasing anti-malarials in drugstores Breakdown of consumers by SES: August vs. November % of 608 (Aug.) and 443 (Nov.) exit interview customers August November 43% 33% 27% 28% 29% 28% 11% 1% Quintile 2 “Poor” Quintile 3 “Neither rich nor poor” Quintile 4 “Richer” Quintile 5 “Richest” 19 The occurrence and duration of stock outs in public/NGO health facilities varies significantly by district, perhaps acting as a driver for private sector treatment-seeking behavior Percent of public/NGO health facilities reporting a stock out in last 3 months % of 104 facilities surveyed 34% Maswa Kongwa Shinyanga Rural Maswa also has the highest numbers of consumers seeking antimalarial treatment in the private sector 11% 21% 20 Today’s presentation Background and context Results to date Implications and areas for further exploration Next steps and timeline 21 The preliminary Month 1 findings from highlight potential areas for further exploration on private sector treatment-seeking in general… Area Implication Socioeconomic status • Continuing lack of consumers from lowest SES quintile in private sector drugstores how can they be reached? Access for children U5 • Drug shops seem not to be the preferred access point for caregivers of children under 5 Drivers of product choice • The importance of shopkeeper recommendation how to ensure appropriate knowledge and incentives? Treatment-seeking in public vs. private sectors • The number of people seeking treatment in the private sector may be linked to public sector ACT availability 22 … and specifically on subsidized ACTs Area Implication Pricing • SRP adherence appears to be high, although price is lower in the non-SRP district Uptake and displacement • Stocking of subsidized ACTs by store owners has occurred rapidly, although it will take time to penetrate all stores • It appears that the subsidized ACT is most displacing AQ, as SP and other anti-malarials’ sales are staying relatively constant 23 Today’s presentation Background and context Results to date Implications for global and national ACT subsidy efforts Next steps and timeline 24 The project will run for one full year, with quarterly procurement, data collection and reporting 2007 June 2008 July Aug. Sept. Oct. Nov. Month 1 data collection Selection + contracting of M&E and social mkting orgs Dec. Jan. Feb. Q1 data collection Mar. Apr. May Q2 data collection June July Aug. Q3 data collection Sept. Q4 data collection Selection + contracting of wholesaler partner Baseline data collection Q1 ACT procurement + distribution Q2 ACT procurement + distribution Q3 ACT procurement + distribution Q4 ACT procurement + distribution Supporting interventions – social marketing, marking of SRP 25 The lessons learned from the pilot will directly inform the planned nationwide scale-up, funded by Global Fund Round 7 • Tanzania’s Global Fund Round 7 grant provides for a nationwide subsidy of ACTs for Under-5s in private sector drug shops – both duka la dawa baridi and ADDO • Key elements will include: – Repackaging – Dispenser training – Social marketing • The Ministry of Health and Social Welfare, with the support of partners, will be moving towards rapid implementation 26 ASANTENI SANA! 27